← Back to patent-cliff list
KRP-116D (Kyorin Pharmaceutical)
Tier C — Watch / tradeKRP-116D (Kyorin Pharmaceutical)
Kyorin Pharmaceutical Co Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Indications (approved)：间质性膀胱炎, Squamous cell carcinoma, 鳞状细胞肿瘤, 皮肤肿瘤
Regional status
US
Phase I
2023-06-12
EU
-
China
-
Japan
Phase III
2017-05-25
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of KRP-116D (Kyorin Pharmaceutical)?
Approved indications include: 间质性膀胱炎, Squamous cell carcinoma, 鳞状细胞肿瘤, 皮肤肿瘤.
When does the KRP-116D (Kyorin Pharmaceutical) patent expire?
No public expiry year is available for KRP-116D (Kyorin Pharmaceutical) yet; this page updates once verified.
How do I get a quote for KRP-116D (Kyorin Pharmaceutical) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09